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Trichoderma fungaemia in a neutropenic
patient with pulmonary cancer and human
immunodeﬁciency virus infection
10.1111/j.1469-0691.2008.02111.x
A 58-year-old man who has been infected with
human immunodeﬁciency virus (HIV) since
1986 presented with fully suppressed plasma
HIV replication while undergoing combination
antiretroviral therapy, and with a persistent
cellular immune deﬁciency (CD4 cell count =
212 ⁄mm3). In 2005, he had been diagnosed
with bronchopulmonary adenocarcinoma
(T2N0M0), and a lobectomy was undertaken
and adjunctive chemotherapy was given. At ﬁrst
tumour relapse in 2006, he was treated with
three cycles of chemotherapy and radiotherapy.
In March 2007, a second relapse was diagnosed,
and treatment with carboplatine, vinorelbine
and steroids (solumedrol 120 mg at day 1 and
oral methylprednisolone 40 mg at day 2) was
initiated on 13 April. After the ﬁrst treatment
cycle, the patient presented with a febrile
aplasia, and co-amoxiclav and oﬂoxacin were
prescribed. A second chemotherapy cycle was
completed on 22 May, and on 25 May, the
patient presented with a 1-day history of fever,
chills and abdominal pain. Upon admission, his
temperature was 38.5C, his heart rate was
130 beats ⁄min and his blood pressure was
130 ⁄ 80 mmHg. Clinical examination revealed a
generalized abdominal tenderness and diar-
rhoea, as well as severe leukopenia (leukocyte
count, 300 ⁄mm3; neutrophil count not per-
formed) and anaemia. Urine culture remained
sterile. Chest X-ray showed no inﬁltrate. Treat-
ment with broad-spectrum antibiotics was initi-
ated (piperacillin–tazobactam and amikacin).
Blood cultures obtained from both the central
venous catheter (a long-duration chamber cath-
eter had been in place since 2006) and a
peripheral vein upon admission yielded wild-
type Escherichia coli, suggesting intestinal trans-
location. On day 5 after admission (30 May)
the neutrophil count rose above 500 ⁄mm3, and
treatment with piperacillin–tazobactam was
replaced by treatment with amoxycillin for a
total duration of 9 days. One blood culture
(using BacT ⁄Alert; BioMe´rieux, Lyon, France)
of a sample drawn at admission (25 May) from
a peripheral vein yielded a mould identiﬁed as
Trichoderma longibrachiatum.
Identiﬁcation was conﬁrmed by DNA
ampliﬁcation and sequencing of a fragment,
including the 3¢-end of the 18S rRNA gene,
internal transcribed spacer (ITS)-1, the 5.8S rRNA
gene, ITS-2, and the 5¢-end of the 28S rRNA gene
(ITS-1–ITS-2) (National Reference Centre for
Mycoses, Institut Pasteur, Paris).
The same mould was isolated from two addi-
tional blood cultures (three positive blood cul-
tures in total) drawn from the central venous
catheter on 28 and 31 May, whereas the matching
blood cultures drawn from peripheral veins
remained negative. Intravenous antifungal ther-
apy was initiated with amphotericin B
(1 mg ⁄ kg ⁄day) on 31 May, and the central venous
catheter was removed on 1 June.
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Cultures of both the distal catheter tip and
the catheter body, as well as of sputum, urine
and stools, were negative for Trichoderma. High-
resolution computed tomography scans (both
chest and abdominal) showed no sign of abscess
or fungal dissemination. A computed tomogra-
phy scan of the nose and sinuses showed
focal thickening of the mucosa of the left
maxillar sinus, without signs of sinusitis.
MICs determined according to EUCAST guide-
lines (http://www.escmid.org/Files/EUCAST%
20moulds%20discussion%20document_071019.
pdf) were as follows: amphotericin B, 1 mg ⁄L;
ﬂuconazole, ‡64 mg ⁄L; itraconazole, 2 mg ⁄L;
voriconazole, 0.5 mg ⁄L; posaconazole, 4 mg ⁄L; and
caspofungin, 0.5 mg ⁄L. These results were in
accordance with those of others [1,7,8,10]. After
7 days of empirical treatment with amphoteri-
cin B, treatment was switched to oral vorico-
nazole (400 mg twice-daily on day 1, and then
200 mg twice-daily) for 2 months, this treatment
option being conﬁrmed a posteriori as the best
option in this case. All subsequent blood
cultures remained sterile, and no relapse of
Trichoderma infection was observed after
discontinuation of voriconazole and at follow-
up 4 months later.
In summary, Trichoderma spp. are ubiquitous
ﬁlamentous fungi that are rarely responsible
for human infections [1]. Contamination is mostly
air-related, but exposure to contaminated water or
food could also be responsible [2]. Five species of
Trichoderma have been identiﬁed as human
pathogens: T. longibrachiatum, Trichoderma harzia-
num, Trichoderma koningii, Trichoderma pseudokon-
ingii and Trichoderma viride. T. longibrachiatum is
the speciesmost commonly encountered in the case
of invasive infections. Trichoderma infections have
been reported in patients undergoing immuno-
suppressive therapies (chemotherapy for solid
tumours, haematological malignancies, and after
bonemarrowor solid organ transplantation) and in
patients with peritoneal dialysis. Among the 23
cases reported in the literature so far, infections
included sinusitis, necrotizing stomatitis, abcesses
(pulmonary, brain or liver), ileocolic infections,
catheter-induced ulceronecrotic skin infections,
peritonitis in patients undergoing peritoneal
dialysis, and patients with disseminated infections
[1–9]. Reported mortality rates are as high as 50%.
Diagnosis relies on positive cultures from involved
organs or skin biopsy specimens, and positive
blood cultures have very rarely been reported,
even in disseminated infections.
This unusual case of Trichoderma fungaemia,
without any sign of pulmonary or identiﬁed deep
focus infection or any identiﬁcation of portal of
entry, is, to our knowledge, the ﬁrst such case
reported to have been resolved by treatment with
amphotericin B and voriconazole . Despite nega-
tive catheter culture, the catheter remains the most
likelyportal of entry in this case, as nodeep focus of
infection was identiﬁed; and among the three
blood cultures positive for Trichoderma, the last
two were drawn from the catheter, whereas
matching blood cultures drawn from peripheral
veinswere negative.Although correlation between
in vitro susceptibility results and clinical response
remains uncertain for moulds, determination of
MICs should be performed in cases of unusual
fungi in order to detect high MICs [11,12].
In the present case, chemotherapy-induced
neutropenia, associated with HIV-induced cellu-
lar immunodeﬁciency, placed the patient at risk
for mould infection. Prompt diagnosis of this
fungal infection, rapid initiation of antifungal
therapy, and perhaps also the removal of the
catheter, led to a favourable outcome.
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